SCHEMBL4478845

SCHEMBL4478845

Cc1noc(C)c1CN[C@H]1CC[C@H](Cc2nc(NCc3ccccc3OC(F)(F)F)nc(N)c2[N+](=O)[O-])CC1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 3/20 0.43
NTRK1 P04629 1/20 0.34
EPHX2 P34913 3/20 0.34
MAPT P10636 3/20 0.33
GAA P10253 1/20 0.33
SMN1; SMN2 Q16637 2/20 0.33
DCPS Q96C86 1/20 0.33
MAPK1 P28482 1/20 0.32
LMNA P02545 3/20 0.32
ALDH1A1 P00352 2/20 0.32
USP2 O75604 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2D6 P10635 1/20 0.32
CYP2C9 P11712 1/20 0.32
TSHR P16473 1/20 0.32
CYP2C19 P33261 1/20 0.32
HSD17B10 Q99714 1/20 0.32
HPGD P15428 1/20 0.32
TDP1 Q9NUW8 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4477310 0.87 PRKCQ (0.48) PRKCQEPHX2MAPTGAASMN1; SMN2
SCHEMBL4479734 0.86 PRKCQ (0.48) PRKCQEPHX2MAPTSMN1; SMN2MAPK1
SCHEMBL4484412 0.86 PRKCQ (0.47) PRKCQEPHX2MAPTDCPSCYP3A4
SCHEMBL4472728 0.85 PRKCQ (0.47) PRKCQEPHX2MAPTDCPSCYP1A2
SCHEMBL4472436 0.85 PRKCQ (0.46) PRKCQEPHX2MAPTSMN1; SMN2MAPK1
SCHEMBL4477353 0.85 PRKCQ (0.44) PRKCQEPHX2MAPTGAASMN1; SMN2
SCHEMBL4480711 0.85 PRKCQ (0.49) PRKCQEPHX2MAPTGAADCPS
SCHEMBL4475018 0.84 PRKCQ (0.47) PRKCQEPHX2MAPTGAADCPS
SCHEMBL4472726 0.83 PRKCQ (0.44) PRKCQNTRK1EPHX2MAPTGAA
SCHEMBL4477462 0.83 PRKCQ (0.48) PRKCQEPHX2MAPTDCPSGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7601714-B2 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2009-10-13 US disclosed
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BARBOSA ANTONIO J M 2008-11-20 US disclosed
EP-1765791-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2007-03-28 EP disclosed
WO-2006014482-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-09 WO disclosed
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2006-02-02 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080287410-A1 PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF PKC-THETA PRKCZ, PRKCQ, PRKCH PRKCQ 2/4885NTRK1 4342/4885EPHX2 861/4885
US-20060025433-A1 Pyrimidine derivatives useful as inhibitors of PKC-theta PRKCZ, PRKCQ, PRKCH PRKCQ 2/4885NTRK1 4342/4885EPHX2 861/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.